Notice of Proposed Sale · 144
Guardant Health, Inc.
GHNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Guardant Health, Inc.
- Issuer CIK
- 0001576280
- SEC file number
- 001-38683
- Phone
- 855-698-8887
- Person for whose account securities are to be sold
- Monroe Terilyn J.
- Relationships to issuer
- Officer
- Street
- 3100 HANOVER STREET
- City
- PALO ALTO
- State / country code
- CA
- Postal code
- 94304
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 46,300 | 7,645,219.00 | 134,196,170 | 08/12/2026 | NASDAQ | Charles Schwab & Co., Inc. |
Broker / market maker — proposed row 1, entry 1
- Name
- Charles Schwab & Co., Inc.
- Street
- 3000 Schwab Way
- City
- Westlake
- State / country code
- TX
- Postal code
- 76262
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/12/2026 | Employee Stock Option Exercise | Guardant Health, Inc. | 46,300 | N | 08/12/2026 | Broker Payment for Cashless Exercise |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/12/2026
- Signed
- Terilyn J. Monroe
Company context
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.